|Ms. Saundra Pelletier||Pres, CEO & Director||1.84M||N/A||1970|
|Mr. Justin J. File||Chief Financial Officer||1.01M||N/A||1970|
|Mr. Russell Barrans||Chief Commercial Officer||762.98k||N/A||1960|
|Ms. Amy Raskopf||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Alexander A. Fitzpatrick Esq.||Exec. VP, Gen. Counsel & Sec.||N/A||N/A||1967|
|Kathy Gallo-Doyle||VP of Sales||N/A||N/A||N/A|
|Dr. Kelly Culwell M.D.||Chief Medical Officer||N/A||N/A||1974|
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Evofem Biosciences, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 10.